The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Abstract
Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The epidemiology of bladder cancer varies by region, with tobacco smoking, occupational exposures (e.g., aromatic amines), and arsenic contamination of drinking water among the putative causes in industrialized countries.159,160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Diverging bladder cancer incidence trends have been observed by sex since the 1990s, with rates tending to decrease or stabilize in men but increase among women in certain European countries (e.g., in Spain, the Netherlands, Germany, and Belarus).160,162,163”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.160,166”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Of note, there may be artifactual changes in incidence because of differences in coding and registration practice concerning inclusion or otherwise of noninvasive carcinomas.160,166,167”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“increases in mortality rates have also been reported among men in Thailand, Israel, and Slovakia and among women in Thailand, Japan, Croatia, and Poland.160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citationCancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,212
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Research works printed but not linked: 1
- Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Chen, Y., Yin, L., Hao, M., Xu, W., Gao, J., Sun, Y., Wang, Q., Chen, S., Liang, Y., Guo, R., et al. (2023) · Acta Pharmaceutica · doi:10.2478/acph-2023-0016 · Cited by 15
Jakus, D., Šolić, I., Jurić, I., Borovac, J. A., & Šitum, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134259 · Cited by 15
Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma
Yoo, D. S., Min, K., Pyo, J., & Kim, N. Y. (2023) · Medicina · doi:10.3390/medicina59081452 · Cited by 15
CT Image-Based Radiomic Analysis for Detecting PD-L1 Expression Status in Bladder Cancer Patients
Cao, Y., Zhu, H., Li, Z., Liu, C., & Ye, J. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.02.047 · Cited by 17
Deciphering the mysteries of MEG3 LncRNA and its implications in genitourinary cancers
Assal, R. A., Rashwan, H. H., Zakaria, Z. I., Sweillam, J. H., Fouda, Y. M., Abdelhamid, A. M., & Youness, R. A. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1519103 · Cited by 16
Tang, G., Zhen, Y., Xie, W., Wang, Y., Chen, F., Qin, C., Yang, H., Du, Z., Shen, Z., Zhang, B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23896 · Cited by 16
The relationship between microRNAs and Rab family GTPases in human cancers
Shahabi, A., Naghili, B., Ansarin, K., & Zarghami, N. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28038 · Cited by 14
Gurung, P. M. S., Barnett, A. R., Wilson, J. S., Hudson, J., Ward, D. G., Messing, E. M., & Bryan, R. T. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.02.012 · Cited by 15
Xiang, M., Yuan, W., Zhang, W., & Huang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10143 · Cited by 16
Downregulation of FoxM1 inhibits cell growth and migration and invasion in bladder cancer cells.
Yang, X., Shi, Y., Yan, J., & Fan, H. (2018) · PubMed Central · Cited by 15
Yu, E. Y.-W., Wesselius, A., van Osch, F., Stern, M. C., Jiang, X., Kellen, E., Lu, C., Pohlabeln, H., Steineck, G., Marshall, J. R., et al. (2019) · Cancer Causes & Control · doi:10.1007/s10552-019-01191-1 · Cited by 15
Calò, B., Sanguedolce, F., Fortunato, F., Stallone, G., d’Altilia, N., Chirico, M., Falagario, U. G., Mancini, V., Carrieri, G., & Cormio, L. (2019) · Medicine · doi:10.1097/md.0000000000016223 · Cited by 15
Rexin, P., Tauchert, A., Hänze, J., Heers, H., Schmidt, A., Hofmann, R. W., & Hegele, A. (2018) · Anticancer Research · doi:10.21873/anticanres.12517 · Cited by 15
Shi, H., Li, J., Li, K., Yang, X., Zhu, Z., & Tian, D. (2019) · Journal of International Medical Research · doi:10.1177/0300060519864806 · Cited by 15
Shi, C., Sun, L., Liu, S., Zhang, E., & Song, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.921087 · Cited by 15
Living With Urinary Diversions: Patient Insights to Improve the Perioperative Experience
Klein, G. T., Ajay, D., Volk, R. J., Leal, V. B., & Westney, O. L. (2021) · Urology · doi:10.1016/j.urology.2021.01.009 · Cited by 15
Ooi, E. H., Popov, V., Alfano, M., & Cheong, J. K. K. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1771437 · Cited by 15
Song, Y., Jin, D., Chen, J., Liang, W., & Liu, X. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa087 · Cited by 15
CASC9 Facilitates Cell Proliferation in Bladder Cancer by Regulating CBX2 Expression
Huo, W., Tan, D., & Chen, Q.-B. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000507828 · Cited by 15
Arora, A. M., Pugliesi, F. G., Zugail, A. S., Moschini, M., Pazeto, C. L., Macek, P., Stabile, A., Lanz, C., Mombet, A., Bennamoun, M., et al. (2020) · Journal of Endourology · doi:10.1089/end.2020.0112 · Cited by 15
Creta, M., Fusco, F., Rocca, R. L., Capece, M., Celentano, G., Imbimbo, C., Imperatore, V., Russo, L., Mangiapia, F., Mirone, V. G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072191 · Cited by 15
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors
Mollica, V., Maggio, I., Antonio Lopez-beltran, B., Montironi, R., Cimadamore, A., Liang Cheng, C., Rizzo, A., Giunchi, F., Schiavina, R., Fiorentino, M., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1807334 · Cited by 15
Wang, Y., Yang, T., Han, Y., Ren, Z., Zou, J., Liu, J., & Xi, S. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3035624 · Cited by 15
RetractedNon-muscle invasive bladder cancer tissues have increased base excision repair capacity
Somuncu, B., Keskin, S., Antmen, F. M., Sağlıcan, Y., Ekmekcioglu, A., Ertuzun, T., Tuna, M. B., Öbek, C., Wilson, D. M., İnce, Ü., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73370-z · Cited by 15
Retinoic acid signaling and bladder cancer: Epigenetic deregulation, therapy and beyond
Ozgun, G., Şentürk, Ş., & Erkek, S. (2020) · International Journal of Cancer · doi:10.1002/ijc.33374 · Cited by 15
El‐Gedamy, M. S., El-Khayat, Z., Abol‐Enein, H., Elsaid, A. M. M., & El-Nahrery, E. M. A. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155355 · Cited by 16
Ding, Y., Liu, N., Chen, M., Xu, Y., Fang, S., Xiang, W., Hua, X., Chen, G., Zhong, Y., & Yu, H. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02231-4 · Cited by 15
Possible connection between diet and microRNA in cancer scenario
Otsuka, K., & Ochiya, T. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.014 · Cited by 16
Rizzo, A., Mollica, V., Santoni, M., Ricci, A. D., Gadaleta‐Caldarola, G., Montironi, R., & Massari, F. (2022) · Future Oncology · doi:10.2217/fon-2021-0841 · Cited by 15
Liu, D., Xu, S., Chang, T., Ma, S., Wang, K., Sun, G., Chen, S., Xu, Y., & Zhang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.916800 · Cited by 15
Li, G., Wu, S., Chen, W., Duan, X., Sun, X., Li, S., Mai, Z., Wu, W., Zeng, G., Liu, H., et al. (2023) · Small Methods · doi:10.1002/smtd.202201313 · Cited by 18
The efficacy of Apaziquone in the treatment of bladder cancer
Masana, F. C., & de Reijke, T. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1392510 · Cited by 15
Pembrolizumab for the treatment of bladder cancer
Sundahl, N., Rottey, S., Maeseneer, D. D., & Ost, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1421461 · Cited by 14
Zhang, X., Chen, Y., Dong, L., & Shi, B. (2018) · Oncology Letters · doi:10.3892/ol.2018.7727 · Cited by 15
Chen, J., Zhang, M., Zhang, X., Cui, Y., Liu, P., Hu, J., Li, H., Jin, H. M., Liu, L., Chen, M., et al. (2018) · Journal of Cancer · doi:10.7150/jca.25811 · Cited by 15
PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials
Hsu, M. M., & Balar, A. V. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.009 · Cited by 15
Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
Yang, H., Yang, C., Wu, C., Wang, L.-J., & Lu, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133162 · Cited by 15
Maheshwari, P. N., Arora, A. M., Sane, M. S., & Jadhao, V. (2020) · Indian Journal of Urology · doi:10.4103/iju.iju_348_19 · Cited by 15
The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression
Ide, H., Inoue, S., & Miyamoto, H. (2018) · Cancers · doi:10.3390/cancers10120484 · Cited by 14
Wieczorek, E., & Garstka, M. A. (2020) · International Journal of Cancer · doi:10.1002/ijc.33359 · Cited by 14
SERPINE2 Overexpression Is Associated with Poor Prognosis of Urothelial Carcinoma
Chuang, H., Hsia, K.-T., Liao, J.-B., Yeh, C.-C., Kuo, W., & Yang, Y. (2021) · Diagnostics · doi:10.3390/diagnostics11101928 · Cited by 14
Increased risk of bladder cancer in young adult men with hyperlipidemia
Shih, H.-J., Lin, K.-H., Wen, Y.-C., Fan, Y.-C., Tsai, P.-S., & Huang, C.-J. (2021) · Medicine · doi:10.1097/md.0000000000028125 · Cited by 14
Grading Systems for Canine Urothelial Carcinoma of the Bladder: A Comparative Overview
Brambilla, E., Govoni, V. M., Cavalca, A. M. B., Amorim, R. L., Fonseca‐Alves, C. E., & Grieco, V. (2022) · Animals · doi:10.3390/ani12111455 · Cited by 14
Sung, C.-J., Wang, H., Sun, K., Hsieh, C.-C., Huang, R., Sun, G., & Tang, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.09.047 · Cited by 15
Chen, L., Yang, J., Long, X., Dong, T., Cheng, Q., Wang, W., Zou, Y., Su, Y., Dai, W., Chen, B., et al. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666221026121600 · Cited by 14
Mathur, P., Santos, C. D. B., Lachuer, H., Patat, J., Latgé, B., Radvanyi, F., Goud, B., & Schauer, K. (2023) · Communications Biology · doi:10.1038/s42003-023-04501-1 · Cited by 16
Guo, C. C., Shen, S. S., & Czerniak, B. A. (2023) · Bladder Cancer · doi:10.3233/blc-220106 · Cited by 14
Florensa, D., Mateo, J., Solsona, F., Galván, L., Mesas, M., Piñol, R., Espinosa-Leal, L., & Godoy, P. (2023) · Annals of Epidemiology · doi:10.1016/j.annepidem.2023.06.002 · Cited by 14
Abbas, N. F., Aoude, M., Kourié, H. R., & Al-Shamsi, H. O. (2023) · Asian journal of urology · doi:10.1016/j.ajur.2023.10.001 · Cited by 14
Nedjadi, T., Ahmed, M. E., Ansari, H. R., Aouabdi, S., & Al-Maghrabi, J. A. (2023) · Cancers · doi:10.3390/cancers15235704 · Cited by 14
Fu, S., Shi, H., Fan, Z., Li, J., Luan, T., Dong, H., Wang, J., Chen, S., Zhang, J., Wang, J., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001065 · Cited by 14
Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage
Fan, N., Zhang, L., Wang, Z., Ding, H., & Yue, Z. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206274095231106042833 · Cited by 14
Cheng, S., Li, C., Liu, L., Liu, X., Li, M., Zhuo, J., Wang, J., Zheng, W., & Wang, Z. (2024) · Biology Direct · doi:10.1186/s13062-023-00446-x · Cited by 13
Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer
Ben‐David, R., Galsky, M. D., & Sfakianos, J. P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.04.004 · Cited by 14
Song, D.-M., Shen, T., Feng, K., He, Y., Chen, S., Zhang, Y., Luo, W.-F., Han, L., Tong, M. H., & Jin, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419126 · Cited by 14
Advances in research on malignant tumors and targeted agents for TOP2A (Review)
Zhou, T., Niu, Y., & Li, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13415 · Cited by 18
He, J., Dong, C., Song, X., Qiu, Z., Zhang, H., Jiang, Y., Liu, T., & Man, X. (2025) · Biology Direct · doi:10.1186/s13062-025-00597-z · Cited by 14
Li, K., Li, Y., Zhang, Y., Lv, J., Zhao, T., Dong, Y., Liu, F., Wang, J., Wei, Y., & Zhu, Q. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116903 · Cited by 15
Poyet, C., Thomas, L., Benoit, T. M., Delmo, D. A., Luberto, L., Banzola, I., Günthart, M. S., Sais, G., Eberli, D., Sulser, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15669 · Cited by 14
Li, G., Hu, J., & Niu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18563 · Cited by 14
Identification of BLCAP as a novel STAT3 interaction partner in bladder cancer
Gromova, I., Svensson, S., Gromov, P., & Moreira, J. M. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188827 · Cited by 16
Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?
Akhtar, M., Al‐Bozom, I., Ben‐Gashir, M., & Taha, N. M. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000235 · Cited by 14
Rezaei, F., Tabatabaee, H., Rahmanian, V., Mirahmadizadeh, A., & Hassanipour, S. (2019) · Annals of Global Health · doi:10.5334/aogh.2545 · Cited by 13
Clinical value of microRNA-19a-3p and microRNA-99a-5p in bladder cancer
Borkowska, E. M., Kutwin, P., Rolecka, D., Konecki, T., Borowiec, M., & Jabłonowski, Z. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.89700 · Cited by 14
Wang, X., Meng, R., & Hu, Q.-M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00180 · Cited by 14
Expression and Prognostic Values of the Roof Plate-Specific Spondin Family in Bladder Cancer
Gao, L., Meng, J., Zhang, M., Fan, S., Gao, S., Wang, X., & Liang, C. Y. (2020) · DNA and Cell Biology · doi:10.1089/dna.2019.5224 · Cited by 14
The Biogenesis, Functions, and Roles of circRNAs in Bladder Cancer
Li, C., Fu, X., He, H., Chen, C., Wang, Y., & He, L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s245233 · Cited by 14
Ou, N., Song, Y., Liu, M., Zhu, J. W., Yang, Y., & Liu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.532924 · Cited by 14
Short-term mortality risks among patients with non-metastatic bladder cancer
Zhai, M., Tang, C., Li, M., Chen, X., Jin, Y., Ying, X., Tang, Z., Wang, X., Wu, Y., Sun, C., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07655-x · Cited by 15
Down-regulation LncRNA-SNHG15 contributes to proliferation and invasion of bladder cancer cells
Mokhtar, A.-D., Kong, C., Zhang, Z., & Du, Y. (2021) · BMC Urology · doi:10.1186/s12894-021-00852-1 · Cited by 14
El‐Gedamy, M. S., El-Khayat, Z., Abol‐Enein, H., Elsaid, A. M. M., & El-Nahrery, E. M. A. (2021) · Immunogenetics · doi:10.1007/s00251-021-01205-w · Cited by 15
Weyerer, V., Strissel, P. L., Strick, R., Sikic, D., Geppert, C. I., Bertz, S., Lange, F., Taubert, H. W., Wach, S., Breyer, J., et al. (2021) · Cancers · doi:10.3390/cancers13102327 · Cited by 14
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Schulz, G. B., Todorova, R., Braunschweig, T. A., Rodler, S., Volz, Y., Eismann, L., Pfitzinger, P. L., Jokisch, F., Büchner, A., Stief, C. G., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.06.001 · Cited by 14
The Emerging Functions of Circular RNAs in Bladder Cancer
Sun, K., Wang, D., Yang, B. B., & Ma, J. (2021) · Cancers · doi:10.3390/cancers13184618 · Cited by 14
Rammant, E., Fonteyne, V., Goethem, V. V., Verhaeghe, S. T. L., Raes, A., Hemelrijck, M. V., Mohamed, N., Decaestecker, K., & Hecke, A. V. (2021) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2021.151226 · Cited by 14
Hagimoto, H., Makita, N., Mine, Y., Kokubun, H., Murata, S., Abe, Y., Kubota, M., Tsutsumi, N., Yamasaki, T., & Kawakita, M. (2021) · BMC Urology · doi:10.1186/s12894-021-00946-w · Cited by 14
Yao, X., Qi, X., Wang, Y., Zhang, B., He, T., Yan, T., Zhang, L., Wang, Y., Zheng, H., Zhang, G., et al. (2022) · Biology · doi:10.3390/biology11020259 · Cited by 14
Li, Z., Liu, J., Fu, H., Li, Y., Liu, Q., Song, W., & Zeng, M. (2022) · Aging · doi:10.18632/aging.204333 · Cited by 14
Pichler, R., Tulchiner, G. A., Oberaigner, W., Schaefer, G., Horninger, W., Brunner, A., & Heidegger, I. M. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.03.003 · Cited by 14
Skowron, M. A., Niegisch, G., Albrecht, P., van Koeveringe, G. A., Romano, A., Albers, P., Schulz, W. A., & Hoffmann, M. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081680 · Cited by 14
Lin, C. D., Travis, R. C., Appleby, P. N., Tipper, S. J., Weiderpass, E., Chang-Claude, J. C., Gram, I. T., Kaaks, R., Kiemeney, L. A. L. M., Ljungberg, B., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31650 · Cited by 14
Makboul, R., Hassan, H. M., Refaiy, A., Abdelkawi, I. F., Shahat, A. A., Hameed, D. A., Morsy, A., Salah, T., & Mohammed, R. A. A. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.04.011 · Cited by 14
Long noncoding RNAs in bladder cancer prognosis: A meta-analysis
Zhu, W. J., Liu, H., Wang, X., Lu, J., & Yang, W. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.04.021 · Cited by 14
Luo, J., & Xu, X. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz187 · Cited by 15
Zhu, S., Huang, Z., & Nabi, G. (2019) · Biomedical Optics Express · doi:10.1364/boe.380629 · Cited by 14
Perioperative immunotherapy in muscle-invasive bladder cancer
Lee, H. H., & Ham, W. S. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.36 · Cited by 13
Novel serum peptide model revealed by MALDI-TOF-MS and its diagnostic value in early bladder cancer
Ding, D., Chen, M., Xiao, X., Cao, P., & Li, S. (2020) · The International Journal of Biological Markers · doi:10.1177/1724600820935473 · Cited by 14
Tamalunas, A. J., Volz, Y., Schlenker, B., Büchner, A., Kretschmer, A., Jokisch, F., Rodler, S., Schulz, G. B., Eismann, L., Pfitzinger, P. L., et al. (2020) · Urologia Internationalis · doi:10.1159/000510137 · Cited by 14
Rosiello, G., Palumbo, C., Pecoraro, A., Luzzago, S., Deuker, M., Stolzenbach, L. F., Tian, Z., Andrea Gallina, A., Gandaglia, G., Montorsi, F., et al. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.09.004 · Cited by 14
The Prognostic Value of Cytokeratin and Extracellular Collagen Expression in Urinary Bladder Cancer
Ingenwerth, M., Nyírády, P., Hadaschik, B. A., Szarvas, T., & Reis, H. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666210225100041 · Cited by 14
Li, X., Fu, S., Huang, Y., Luan, T., Wang, H., & Wang, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-09006-w · Cited by 14
CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future
Zhang, Z., Li, D., Yun, H., Liu, W., Chai, K., Tong, J., Zeng, T., Gao, Z., & Xie, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.915171 · Cited by 15
Murakami, K., Kita, Y., Sakatani, T., Hamada, A., Mizuno, K., Nakamura, K. D., Takada, H., Matsumoto, K., Sano, T., Goto, T., et al. (2021) · Cancer Science · doi:10.1111/cas.15051 · Cited by 13
DNA Methylome Changes of Muscle- and Neuronal-Related Processes Precede Bladder Cancer Invasiveness
Bošković, M., Roje, B. M., Chung, F. F., Gelemanović, A., Cahais, V., Cuenin, C., Khoueiry, R., Vilović, K., Herceg, Z., & Terzić, J. (2022) · Cancers · doi:10.3390/cancers14030487 · Cited by 13
Clinical Potential of Fruit in Bladder Cancer Prevention and Treatment
Wigner, P., Bijak, M., & Saluk, J. (2022) · Nutrients · doi:10.3390/nu14061132 · Cited by 15
Deng, L., Jin, K., Zhou, X., Zhang, Z., Ge, L., Xiong, X., Su, X., Jin, D., Yuan, Q., Zhang, C., et al. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac007 · Cited by 14
Cao, W., Shao, Y., Wang, N., Jiang, Z., Sun, Y., & Wang, J. (2022) · Biomarkers in Medicine · doi:10.2217/bmm-2022-0409 · Cited by 13
Wu, Y., Deng, Y., Dai, Z., Ma, Y., Lyu, L., Chen, L., Zheng, Y., Li, Y., Wang, Z., & Gao, J. (2023) · Cancer Medicine · doi:10.1002/cam4.6219 · Cited by 13
Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer
Silva, A., Félix, A., Cerqueira, M. C., Gonçalves, C. S., Sampaio‐Marques, B., Longatto‐Filho, A., Baltazar, F., & Afonso, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122688 · Cited by 14
Tumor cell dissociation‐enhanced intravesical chemotherapy of orthotopic bladder cancer
Ma, Z., Sun, Z., Ye, Z., Cai, K., Zhong, W., Yuan, W., Zhang, W., Zhang, J., Zhang, K., Liang, H., et al. (2024) · SmartMat · doi:10.1002/smm2.1276 · Cited by 13
Metadata
- Authors
- Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- American Cancer Society (US)
- Corresponding author
- Bray, Freddie
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 71
- Issue
- 1
- Pages
- 96-108
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2473162054
- Cited by
- 2,514
- References
- 55
- Citations by year
- 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
- MeSH terms
- Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
